(TOI) The Oncology Institute, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TOI) The Oncology Institute, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This The Oncology Institute, Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing approach, distribution channels, and promotional tactics to support marketing research and strategy. This page includes a real preview/sample of the analysis so you can review format and content; purchase the full version to download the complete ready-to-use report.
Product
Physician-led oncology care
The Oncology Institute, Inc. centers its main product on physician-led oncology care for adult and senior patients, covering diagnosis, treatment planning, and ongoing management by oncology doctors. This is the company’s core clinical service line and the one that drives most patient visits and revenue.
On-site infusion services
On-site infusion services let The Oncology Institute, Inc. deliver IV cancer therapy inside its own clinic network, so patients get treatment and physician oversight in one place. This model supports tighter coordination, faster starts, and fewer handoffs than sending patients to outside infusion centers. For oncology care, that same-location setup can improve convenience and keep revenue tied to the clinic visit.
Medication dispensing
The Oncology Institute, Inc. includes in-house medication dispensing, so patients can get prescribed oncology drugs through the same care system. This supports treatment continuity and faster starts, which matters when oncology therapy changes often. In its latest filings, TOI also reported about $400M+ in annual revenue, showing this service sits inside a scaled care model.
Radiation therapy
Radiation therapy broadens The Oncology Institute, Inc.’s care mix beyond office-based oncology visits, giving patients access to a core cancer treatment used in many solid tumors. The American Cancer Society projects 2.04 million new U.S. cancer cases in 2025, so adding this modality helps TOI serve a larger share of total treatment need and deepen referral capture.
- Expands care beyond clinic visits
- Adds a major oncology modality
- Supports broader patient retention
Clinical trials and supportive programs
In 2025, The Oncology Institute, Inc. broadens its product mix beyond routine oncology care with clinical trials, palliative care, stem cell transplant outpatient programs, transfusions, and patient support services. That wider offer helps meet more complex cancer needs and can deepen patient retention.
- Clinical trials add advanced treatment access.
- Palliative care and transfusions expand support.
- Outpatient transplants raise care complexity.
Bundled Oncology Care Driving $400M+ Revenue
The Oncology Institute, Inc. sells a bundled oncology care product: physician-led visits, infusion, oral drug dispensing, radiation, trials, palliative care, and transplant support. This mix keeps treatment in-house and supports retention; the company reported about $400M+ in annual revenue in its latest filings.
| Product element | Value |
|---|---|
| Core care | Physician-led oncology |
| Ancillary care | Infusion, drugs, radiation |
| Complex care | Trials, palliative, transplants |
| Revenue scale | $400M+ annual |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P’s analysis of The Oncology Institute, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Distills The Oncology Institute’s 4Ps into a quick, clear snapshot that reduces analysis overload and speeds decision-making.
Reference Sources
Provides a concise, traceable list of primary sources—industry reports, clinical databases, and government datasets—to speed due diligence and validate The Oncology Institute’s market and financial assumptions.
Place
67 clinic locations
The Oncology Institute, Inc. operates 67 clinic locations, giving it a wide physical footprint across local markets. This supports its Place strategy by delivering oncology care through outpatient sites close to patients. A large clinic network also helps TOI reach more referrals and keep care accessible without hospital-based visits.
United States footprint
The Oncology Institute’s U.S. footprint is built on a clinic-led model, not one central hospital, so patients can get care closer to home. In FY2025, that multi-site network helped the Company serve cancer patients across several U.S. markets and improve local access. This setup reduces travel burden and supports faster treatment starts.
Cerritos, California headquarters
The Oncology Institute, Inc. is headquartered in Cerritos, California, and that base anchors administration, clinical operations, and network management. Cerritos is in Los Angeles County, so the location keeps the company close to California’s large oncology market and referral network. The California base also reinforces the company’s West Coast identity and operating roots.
Clinic-based outpatient model
The Oncology Institute, Inc. uses clinic-based outpatient sites as its main place channel for physician visits, infusion, and support care. This setup fits repeated oncology use, because patients return often for treatment and monitoring instead of one-off visits.
- Outpatient clinics drive recurring patient access.
- Infusion and visits stay in one care flow.
- Supports repeat use, not episodic care.
On-site treatment delivery
The Oncology Institute, Inc. delivers many treatments at the same clinic where patients are seen, including infusion, medication dispensing, and some advanced programs. That one-site model cuts extra travel and handoffs, which matters in cancer care where speed and continuity can shape the patient experience.
- Infusion stays clinic-based.
- Medication access is on-site.
- Fewer provider-to-provider transfers.
TOI’s 67 Clinics Bring Oncology Care Closer to Patients
The Oncology Institute, Inc. uses 67 clinic locations and a Cerritos, California base to keep care close to patients and referrals. Its Place model centers on outpatient oncology, with infusion and follow-up delivered in the same local site. That reduces travel and supports repeat treatment in FY2025.
| Metric | FY2025 |
|---|---|
| Clinic locations | 67 |
| HQ | Cerritos, CA |
Preview Before You Purchase
The Oncology Institute, Inc. Reference Sources
The preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This Oncology Institute, Inc. 4P's Marketing Mix analysis is complete, editable, and ready to use, covering Product, Price, Place, and Promotion with actionable insights and examples tailored to oncology services and specialty clinics.
Promotion
Physician referral network
TOI’s promotion depends heavily on physician referrals, especially from primary care doctors, specialists, and hospitals. In the U.S., the American Cancer Society projects about 2.0 million new cancer cases in 2025, so referral access is a direct driver of patient flow. This channel is valuable because trust and clinical handoffs matter more than broad consumer ads in oncology. Strong referral ties can lower acquisition cost and support steadier volume.
Community oncology positioning
The Oncology Institute, Inc. promotes itself as a specialized community oncology provider, with care delivered through local clinics rather than a hospital-only model. That positioning supports continuity of care, faster access, and a more personal patient experience. It also helps differentiate The Oncology Institute from large hospital systems that can be slower and less localized.
Clinical trial outreach
Clinical trial outreach is a strong message for The Oncology Institute, Inc., because it helps attract patients who want advanced options and gives physicians a clear sign of clinical depth. In the U.S., the American Cancer Society estimated 2.0 million new cancer cases in 2024, so access to trials can matter to a large patient pool. It also supports referrals and partner trust by showing the brand can run complex, research-driven care.
Patient education channels
The Oncology Institute, Inc. uses patient-facing education to explain services and care paths, which matters in a category with about 2.04 million projected U.S. cancer cases in 2025. Digital content and clinic staff communication help build trust, reduce confusion, and support faster treatment decisions. In oncology, clear education can shape whether patients start, stay with, and understand care.
- Explains care paths clearly
- Supports trust through digital content
- Reduces friction in complex choices
- Fits high-stakes oncology decisions
Provider and payer engagement
The Oncology Institute, Inc. uses provider and payer engagement as a key promotion channel, building ties with health plans and care partners to drive referrals and widen access to covered oncology care. In healthcare, these relationships matter because they shape patient flow and reimbursement, not just brand reach. This approach supports visibility with decision-makers who control network access and treatment pathways.
- Drives referrals through care partners
- Improves access to covered care
- Targets payers, not mass ads
How TOI Drives Growth Through Referrals, Payer Ties, and Patient Education
The Oncology Institute, Inc. promotes through referral networks, payer ties, clinic branding, and patient education, not mass ads. That fits U.S. oncology demand: about 2.0 million new cancer cases in 2025, with 2.04 million projected for 2025 in some estimates, so trusted handoffs and clear care paths drive volume.
| Promotion lever | Why it matters |
|---|---|
| Referrals | Drives patient flow |
| Payer ties | Expands covered access |
| Education | Reduces care friction |
Price
Reimbursement-based pricing
The Oncology Institute, Inc.’s pricing is reimbursement-based, so revenue depends on payer contracts, not a shelf price. In 2025, Medicare physician fee schedule payments moved by about 2.8%, while commercial rates still vary by service and plan. That means the realized price on each oncology visit or infusion can differ sharply by payer, code, and site of care.
Insurance-backed revenue
The Oncology Institute, Inc. relies on payer reimbursement, so commercial insurance, Medicare, and Medicaid drive most pricing power. In 2025, U.S. oncologists still received the bulk of collections through third-party payers, with patient cost-sharing usually the smaller after-payor amount. That makes contract rates and prior-authorization terms central to revenue.
Patient cost-sharing
Patients at The Oncology Institute, Inc. still often pay copays, deductibles, or coinsurance, and the amount depends on the plan and service. This is normal in specialty care. For context, Medicare Part B in 2025 has a $257 deductible and usually 20% coinsurance for covered outpatient services.
Service-specific billing
The Oncology Institute, Inc. uses service-specific billing, so price depends on the visit, infusion, procedure, or therapy delivered. That means one oncology episode can carry several reimbursement lines, and the realized price can change a lot by payer and case mix.
This model supports higher billing granularity, but it also makes revenue less predictable because each service can reimburse at a different rate.
- Price varies by service type
- Infusions and procedures bill separately
- Reimbursement shifts by payer mix
- Case-level revenue is highly variable
Trial-related care support
The Oncology Institute, Inc. can soften trial-related costs by steering eligible patients into studies where sponsors often pay 100% of research-only expenses, while routine care may still be billed normally. For patients who qualify, that can cut out-of-pocket costs on selected tests, visits, and trial drugs. In U.S. oncology trials, this cost shift matters because the sponsor, not the patient, funds the study-specific layer.
- Sponsors often cover 100% research costs
- Patients may pay less for covered routine care
- Reduces trial participation cost pressure
Oncology Pricing: Reimbursement Drives Revenue, Not List Price
The Oncology Institute, Inc. sets price through payer reimbursement, not a fixed list price, so realized revenue shifts by Medicare, Medicaid, and commercial contract terms. In 2025, Medicare physician fee schedule payments rose about 2.8%, but oncology collections still depend on service code and site of care.
Copays, deductibles, and coinsurance still hit patients, and Medicare Part B has a $257 deductible in 2025 with about 20% coinsurance. Trial care can lower out-of-pocket costs when sponsors cover research-only expenses.
| Price driver | 2025 data |
|---|---|
| Medicare fee update | +2.8% |
| Medicare Part B deductible | $257 |
| Coinsurance | 20% |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.